If growth for Kedrion means an increased and improved response to the therapeutic needs of patients, in 2021 the company, – – reaffirmed and extended its commitment in Turkey through its Betaphar subsidiary side by side with the world of scientific research, clinicians and patients suffering from rare and debilitating diseases.
It is a responsibility that has taken shape over the last twelve months by promoting, supporting and participating in important events and initiatives. The most recent event was on December 24 in the city of Van in eastern Turkey, when we organized a medical-scientific meeting on the topic of diagnosis and treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), one of the main disorders of the peripheral nervous system.
Also in December, in the field of Immunology, we organized a webinar on Primary Immunodeficiencies (PID) aimed at the local medical community to encourage participants to share knowledge and experience . For this purpose, in October, we also participated in the 7th Turkish Clinical Immunology Congress held remotely, during which we supported a satellite symposium on the topic.
2021 also saw a strong commitment on the part of the company in the area of coagulation disorders. In this therapeutic field, we participated in major national and international conferences, including the XIIth Eurasian Hematology-Oncology Congress (EHOC) in Istanbul and the XVIII International Congress of Hemophilia in Cyprus. On both occasions, we supported a scientific symposium dedicated to explaining current and future roles of Factor VIII-based replacement therapy in the treatment of Hemophilia A.
In 2022 the company will pursue this course by continuing to strengthen its presence in Turkey, with the aim of expanding its therapeutic services in all the areas in which it operates, thereby ensuring that those affected by rare and debilitating diseases can enjoy a better quality of life.
